Аналитики оценили перспективы фармацевтической компании Kyowa Kirin на фоне роста конкурентов

Kyowa Kirin (OTCMKTS:KYKOF – Get Free Report) is one of 903 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Kyowa Kirin to similar businesses based on the strength of its earnings, analyst recommendations, profitability, institutional ownership, dividends, valuation and risk. Analyst Ratings This is a summary of recent recommendations and price targets for Kyowa Kirin and its peers, as reported by MarketBeat.com. As a group, “Pharmaceuticals” companies have a potential upside of 30.19%. Given Kyowa Kirin’s peers stronger consensus rating and higher possible upside, analysts clearly believe Kyowa Kirin has less favorable growth aspects than its peers. Valuation and Earnings Kyowa Kirin’s peers have higher revenue and earnings than Kyowa Kirin. Kyowa Kirin is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry. Dividends Kyowa Kirin pays an annual dividend of $19.94 per share and has a dividend yield of 126.2%. Kyowa Kirin pays out 58.1% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 3.7% and pay out 48.2% of their earnings in the form of a dividend. Profitability This table compares Kyowa Kirin and its peers’ net margins, return on equity and return on assets. Institutional & Insider Ownership 10.3% of Kyowa Kirin shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Summary Kyowa Kirin peers beat Kyowa Kirin on 9 of the 13 factors compared. Kyowa Kirin Company Profile Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; and Romiplate/Nplate, a genetically recombinant protein that produces platelet through the stimulation of thrombopoietin receptors. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, an anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited. Receive News & Ratings for Kyowa Kirin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyowa Kirin and related companies with MarketBeat.com's FREE daily email newsletter.